Key Highlights

• VERAXA Biotech (NASDAQ:VRXA) has initiated cell line development for its lead BiTAC-TCE program in collaboration with ATUM.

• ATUM will apply its Leap-In Transposase technology to generate stable clonal cell lines supporting IND and CTA-enabling activities.

• The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research Annual Meeting.

• VERAXA's BiTAC platform uses a conditional AND-gated design intended to reduce off-tumor toxicity compared with conventional T-cell engagers.

A Manufacturing Milestone Follows Encouraging Preclinical Signals

VERAXA Biotech announced the initiation of cell line development for its lead BiTAC T-cell engager program, marking a step toward the chemistry, manufacturing, and controls work required to advance the candidate toward clinical testing. The company is collaborating with ATUM, which will apply its Leap-In Transposase technology to generate stable clonal cell lines intended to support activities enabling future investigational new drug and clinical trial applications.

This development milestone follows encouraging preclinical data that VERAXA presented at the 2026 American Association for Cancer Research Annual Meeting, providing an early scientific basis for advancing the program into the manufacturing and process development stage. The collaboration is intended to support early process development, analytical method development, and formulation work, alongside production of material needed for nonclinical studies.

A Conditional Activation Design Targets Improved Tumor Selectivity

VERAXA's BiTAC-TCE platform is built around a distinctive mechanism intended to address a longstanding challenge in T-cell engager therapeutics: off-target toxicity. The approach splits the T-cell engager into two complementary precursor components that only combine to form an active therapeutic when both bind separate tumor targets present on the same cell.

This conditional, AND-gated activation mechanism is designed to ensure the therapy activates specifically in the presence of tumor cells expressing both target markers simultaneously, rather than engaging healthy tissue that may express only one of the two targets. The company believes this approach could meaningfully reduce off-tumor toxicity commonly associated with conventional T-cell engager therapies, while preserving the anti-cancer activity that makes this therapeutic class effective against certain malignancies.

Early-Stage Platform Carries Both Scientific Promise and Development Risk

If VERAXA's AND-gated mechanism performs as intended through further development, the approach could potentially enable higher dosing regimens and a broader therapeutic window compared with conventional single-target T-cell engagers, a meaningful potential advantage in a therapeutic class often constrained by toxicity-related dosing limits. The use of ATUM's established Leap-In Transposase technology for cell line development may also help streamline the manufacturing pathway toward IND-enabling studies.

However, the program remains in a relatively early stage, with cell line development representing a preparatory step ahead of the more extensive nonclinical and eventual clinical testing required to validate both safety and efficacy in humans. Biotechnology programs at this stage carry substantial development risk, and the ultimate clinical translation of preclinical AACR data, however encouraging, is not guaranteed. Whether the conditional activation mechanism delivers the anticipated toxicity reduction while maintaining therapeutic efficacy will require substantial additional data from subsequent development stages.

Conclusion

VERAXA Biotech's initiation of cell line development with ATUM represents a meaningful step in advancing its lead BiTAC-TCE candidate toward IND-enabling studies, building on encouraging preclinical data presented earlier this year. The platform's conditional AND-gated design targets a genuine unmet need in T-cell engager therapeutics around tumor selectivity and toxicity management. The program's progression through manufacturing development and into nonclinical studies will likely offer clearer signals of its potential clinical viability in the coming stages.